International Concerted Action to Allocate Children, Adolescents and Young Adults With Relapsed and Refractory Leukemia/Lymphoma to the Right Therapy.

Study Summary

The iLTB is a proof-of-concept initiative for children with r/r hematological malignancies, in which available treatment options will be prioritized by actionable events in a harmonized and uniform setting across Europe by a team of biologists, bio-statisticians, bio-informaticians, disease experts, geneticists, flow-experts, clinical trial physicians and also the treating physician. The iLTB will discuss molecular (genetic lesions), immunophenotypic/surface antigen markers information and, if available, drug response profiles to prioritize these events taking into account the treatment history and treatment intention (bridging to hematopoietic stem cell transplanation/CAR-T or palliative) of each patient followed by a registry to monitor how often iLTB advice has been followed, which other therapy was chosen (off-label, compassionate use) and what the patient outcome is at an aggregated level. As such the iLTB is non-interventional as it mainly provides advice and registers data on patients discussed in the iLTB.

Interventions

Study Locations

Facility	City	State	Country
UH Gent	Ghent		Belgium
Righospitalet	Copenhagen		Denmark
Semmelweis	Budapest		Hungary
Princess Máxima Center for Pediatric Oncology	Utrecht	Utrecht	Netherlands
Vall d'Hebron	Barcelona		Spain
Queen Silvia	Gothenburg		Sweden
Newcastle Hospital	Newcastle		United Kingdom

Official Trial Information

View on ClinicalTrials.gov